Overview

Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy

Status:
Completed

Trial end date:
2005-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and tolerability of atomoxetine alone versus atomoxetine plus low-dose, sustained-release MPH in children with treatment-resistant ADHD.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Atomoxetine Hydrochloride
Central Nervous System Stimulants
Methylphenidate